We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pilot Projects Initiated to Create Cancer Genomics Cloud

By LabMedica International staff writers
Posted on 03 Feb 2014
The US National Cancer Institute (NCI; Rockville, MD, USA) has allotted USD 20 million for cloud-based genomics pilot projects, realizing that it is faced with rising data struggles. More...
Because the scale of its projects increases—one initiative is expected to generate 2.5 petabytes of data—downloading analysis findings on local systems becomes unrealistic.

The NCI is now seeking organizations that can help in its goals, having spent 2013 collecting on user feedback oh what they need from cloud-based cancer genomics. The plan is to promote the development of multiple pilot projects that will undergo a competitive assessment. The NCI, after consulting with cancer researchers, will select one or more of the projects, or a modification of them, as the production version. Finally, the project will be sourced into a Cancer Knowledge Commons that aggregates all data.

The last phase of the project is to optimize NCI-generated data access by decreasing the technical requirements for researchers. Data are downloaded, in the current system, for analysis with locally developed and run tools. The dependence on local systems translates into organizations without top-tier computing power and capabilities can do less with the data. Correspondingly, storing petabytes of data is impractical for some groups. With data pools growing quickly, storage costs will also increase.

The NCI views cloud-based genomics systems will serve as the solution. Storing data and running analysis tools in the cloud will lessen the computing power needed for end users to search for clues in the results. Even prominent research institutions should benefit from using a cloud-based system, as data download times are on the cusp of becoming impractical. Using a point-to-point 10-gigabit network, downloading the 2.5 petabytes generated by the Cancer Genome Atlas would take weeks.

The NCI’s new initiative will be, as aforementioned, the first step toward the establishment of a full Cancer Knowledge Commons, relative to the US National Academy report on Precision Medicine, and will be coordinated with the National Institutes of Health’s (Bethesda, MD, USA) Big Data to Knowledge (BD2K) initiative and other pertinent activities in large-scale data analysis.

Related Links:

US National Cancer Institute



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.